Biotech firms push to exempt orphan drugs from price cuts

A coalition of biotech companies is lobbying the US government to exclude orphan drugs, which treat rare diseases, from new federal pilot programs designed to lower Medicare costs. They argue that price controls could stifle innovation for these critical, often life-saving, treatments. This move could impact access and affordability for patients relying on specialized therapies.